Details About Generic Salt ::  Famotidi

Main Medicine Class:: Histamine H2 antagonist   

(fuh-moE-tih-deen)

Pepcid

Tablets: 20 mg, 40 mg

Powder for Oral Suspension: 40 mg/5 mL when reconstituted

Injection: 10 mg/mL

Injection, pre-mixed: 20 mg/50 mL in 0.9% NaCl

Pepcid AC

Tablets, chewable: 10 mg

Pepcid AC

Tablets: 10 mg

Pepcid AC

Gelcaps: 10 mg

Pepcid RPD

Tablets, orally disintegrating: 20 mg, 40 mg

Apo-Famotidine

Gen-Famotidine

Novo-Famotidine

Nu-Famotidine

Pepcid IV

Class: Histamine H2 antagonist

 Indications Short-term treatment and maintenance therapy for duodenal ulcer, gastroesophageal reflux disease (GERD, including erosive or ulcerative disease), benign gastric ulcer, treatment of pathologic hypersecretory conditions.

Treatment of upper GI bleeding; prevention of stress ulcers; prior to anesthesia for prevention of pulmonary aspiration of gastric acid.

 Contraindications Hypersensitivity to other H₂ antagonists.

 Route/Dosage

Duodenal Ulcer (Active)

PO 40 mg at bedtime or 20 mg bid for 6 to 8 wk. Maintenance: 20 mg at bedtime.

Benign Gastric Ulcer (Acute)

40 mg at bedtime.

GERD

ADULTS: 20 mg bid (max 6 wk). For esophagitis and accompanying symptoms caused by GERD, 20 to 40 mg bid (max 12 wk).

Pathologic Hypersecretory Conditions

ADULTS: Start at 20 mg q 6 hr, continued as clinically indicated; doses up to 160 mg q 6 hr have been used.

Moderate or Severely Impaired Renal Function

(Ccr < 10 mL/min) May need to reduce to half the dose or increase dosing interval to 36 to 48 hr.

Parenteral For hospitalized patients with pathologic hypersecretory conditions or intractable ulcers, or patients unable to take orally: 20 mg IV q 12 hr. Parenteral use in GERD not established.

 Interactions

Ketoconazole: Effects of ketoconazole may be decreased.

 Lab Test Interferences None well documented.

 Adverse Reactions

CARDIOVASCULAR: Palpitations. CNS: Headache; somnolence; fatigue; dizziness; confusion; hallucinations; agitation or anxiety; depression; insomnia; paresthesias. DERMATOLOGIC: Alopecia; rash; pruritus; urticaria; acne; dry skin; flushing. EENT: Tinnitus; taste disorder; orbital edema; conjunctival injection. GI: Diarrhea; constipation; nausea; vomiting; abdominal discomfort; anorexia; dry mouth. GU: Impotence; loss of libido. HEMATOLOGIC: Thrombocytopenia. RESPIRATORY: Bronchospasm. OTHER: Arthralgia; transient pain at injection site; fever.

 Precautions

Pregnancy: Category B. Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Elderly: May have reduced renal function; decreased clearance may occur. Gastric Malignancy: Symptomatic response to famotidine does not preclude gastric malignancy. Hepatic Function Impairment: Use caution; decreased clearance may occur. Hypersensitivity: Rare cases of anaphylaxis have occurred. Renal Function Impairment: Decreased clearance may occur; reduced dose may be needed.

PATIENT CARE CONSIDERATIONS

 Administration/Storage

• To prepare for IV push, dilute 2 mL famotidine (solution containing 10 mg/mL) with 0.9% Sodium Chloride for Injection in 5 to 10 mL volume. Administer over 2 min.
• To prepare IV infusion, dilute 2 mL famotidine (solution containing 10 mg/mL) with 100 mL 5% Dextrose. Other diluents that may be used include 0.9% Sodium Chloride for Injection, 10% Dextrose, Lactated Ringer’s Injection, or 5% sodium bicarbonate. Infuse over 15 to 30 min.
• Keep powder vials away from heat. After reconstitution, store in the refrigerator, but do not freeze. Discard after 30 days.
• Store parenteral solutions in refrigerator. When mixed in polyvinyl chloride minibags, stability is 14 days in refrigerator; if frozen, solution remains stable for 28 days and for 48 hr at room temperature.
• Administer with antacids if necessary.
• Medication may be mixable with TPN. Stability depends on solution used.

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Monitor renal and hepatic function in elderly patients. Notify health care provider of any changes in hepatic or renal function.
• Monitor fluid I&O for possible dosage adjustment.
• Give with antacids if necessary.

 Patient/Family Education

• Instruct patient not to double up on medication if dose is missed, but to wait and take next scheduled dose on time.
• Tell patient to notify health care provider immediately of any black, tarry stool or “coffee-ground” vomit.
• Tell patient to notify health care provider of any shortness of breath, GI disturbances, bleeding, rash, dizziness, or fever.
• Tell patient to shake suspension well before taking.

–>

 

Drugs Class ::

(fuh-moE-tih-deen)

Pepcid

Tablets: 20 mg, 40 mg

Powder for Oral Suspension: 40 mg/5 mL when reconstituted

Injection: 10 mg/mL

Injection, pre-mixed: 20 mg/50 mL in 0.9% NaCl

Pepcid AC

Tablets, chewable: 10 mg

Pepcid AC

Tablets: 10 mg

Pepcid AC

Gelcaps: 10 mg

Pepcid RPD

Tablets, orally disintegrating: 20 mg, 40 mg

Apo-Famotidine

Gen-Famotidine

Novo-Famotidine

Nu-Famotidine

Pepcid IV

Class: Histamine H2 antagonist

Indications for Drugs ::

 Indications Short-term treatment and maintenance therapy for duodenal ulcer, gastroesophageal reflux disease (GERD, including erosive or ulcerative disease), benign gastric ulcer, treatment of pathologic hypersecretory conditions.

Treatment of upper GI bleeding; prevention of stress ulcers; prior to anesthesia for prevention of pulmonary aspiration of gastric acid.

Drug Dose ::

 Route/Dosage

Duodenal Ulcer (Active)

PO 40 mg at bedtime or 20 mg bid for 6 to 8 wk. Maintenance: 20 mg at bedtime.

Benign Gastric Ulcer (Acute)

40 mg at bedtime.

GERD

ADULTS: 20 mg bid (max 6 wk). For esophagitis and accompanying symptoms caused by GERD, 20 to 40 mg bid (max 12 wk).

Pathologic Hypersecretory Conditions

ADULTS: Start at 20 mg q 6 hr, continued as clinically indicated; doses up to 160 mg q 6 hr have been used.

Moderate or Severely Impaired Renal Function

(Ccr < 10 mL/min) May need to reduce to half the dose or increase dosing interval to 36 to 48 hr.

Parenteral For hospitalized patients with pathologic hypersecretory conditions or intractable ulcers, or patients unable to take orally: 20 mg IV q 12 hr. Parenteral use in GERD not established.

Contraindication ::

 Contraindications Hypersensitivity to other H₂ antagonists.

Drug Precautions ::

 Precautions

Pregnancy: Category B. Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Elderly: May have reduced renal function; decreased clearance may occur. Gastric Malignancy: Symptomatic response to famotidine does not preclude gastric malignancy. Hepatic Function Impairment: Use caution; decreased clearance may occur. Hypersensitivity: Rare cases of anaphylaxis have occurred. Renal Function Impairment: Decreased clearance may occur; reduced dose may be needed.

PATIENT CARE CONSIDERATIONS

Drug Side Effects ::

 Adverse Reactions

CARDIOVASCULAR: Palpitations. CNS: Headache; somnolence; fatigue; dizziness; confusion; hallucinations; agitation or anxiety; depression; insomnia; paresthesias. DERMATOLOGIC: Alopecia; rash; pruritus; urticaria; acne; dry skin; flushing. EENT: Tinnitus; taste disorder; orbital edema; conjunctival injection. GI: Diarrhea; constipation; nausea; vomiting; abdominal discomfort; anorexia; dry mouth. GU: Impotence; loss of libido. HEMATOLOGIC: Thrombocytopenia. RESPIRATORY: Bronchospasm. OTHER: Arthralgia; transient pain at injection site; fever.

Drug Mode of Action ::  

(fuh-moE-tih-deen)

Pepcid

Tablets: 20 mg, 40 mg

Powder for Oral Suspension: 40 mg/5 mL when reconstituted

Injection: 10 mg/mL

Injection, pre-mixed: 20 mg/50 mL in 0.9% NaCl

Pepcid AC

Tablets, chewable: 10 mg

Pepcid AC

Tablets: 10 mg

Pepcid AC

Gelcaps: 10 mg

Pepcid RPD

Tablets, orally disintegrating: 20 mg, 40 mg

Apo-Famotidine

Gen-Famotidine

Novo-Famotidine

Nu-Famotidine

Pepcid IV

Class: Histamine H2 antagonist

Drug Interactions ::

 Interactions

Ketoconazole: Effects of ketoconazole may be decreased.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies.
• Monitor renal and hepatic function in elderly patients. Notify health care provider of any changes in hepatic or renal function.
• Monitor fluid I&O for possible dosage adjustment.
• Give with antacids if necessary.

Drug Storage/Management ::

 Administration/Storage

• To prepare for IV push, dilute 2 mL famotidine (solution containing 10 mg/mL) with 0.9% Sodium Chloride for Injection in 5 to 10 mL volume. Administer over 2 min.
• To prepare IV infusion, dilute 2 mL famotidine (solution containing 10 mg/mL) with 100 mL 5% Dextrose. Other diluents that may be used include 0.9% Sodium Chloride for Injection, 10% Dextrose, Lactated Ringer’s Injection, or 5% sodium bicarbonate. Infuse over 15 to 30 min.
• Keep powder vials away from heat. After reconstitution, store in the refrigerator, but do not freeze. Discard after 30 days.
• Store parenteral solutions in refrigerator. When mixed in polyvinyl chloride minibags, stability is 14 days in refrigerator; if frozen, solution remains stable for 28 days and for 48 hr at room temperature.
• Administer with antacids if necessary.
• Medication may be mixable with TPN. Stability depends on solution used.

Drug Notes ::

 Patient/Family Education

• Instruct patient not to double up on medication if dose is missed, but to wait and take next scheduled dose on time.
• Tell patient to notify health care provider immediately of any black, tarry stool or “coffee-ground” vomit.
• Tell patient to notify health care provider of any shortness of breath, GI disturbances, bleeding, rash, dizziness, or fever.
• Tell patient to shake suspension well before taking.

–>

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.